Serious adverse events (proportion) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · people with major upper gastrointestinal, liver and pancreatic surgery
It is very uncertain whether enhanced recovery protocol changes serious adverse events (proportion) compared with standard care (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · patients with oesophageal cancer
It is very uncertain whether laparoscopic changes serious adverse events (proportion) compared with open transhiatal oesophagectomy (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · patients with pancreatic cancer
It is very uncertain whether laparoscopic distal pancreatectomy changes serious adverse events (proportion) compared with open distal pancreatectomy (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) ( · people with primary biliary cholangitis
It is very uncertain whether D‐Penicillamine changes serious adverse events (proportion) ( compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion of patients) · patients with laparoscopic cholecystectomy.
It is very uncertain whether routine abdominal drain changes serious adverse events (proportion of patients) compared with 'no drain' (very low certainty).
1 finding from 1 review
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Proportion of infants with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of infants with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
Proportion of mothers with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of mothers with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with ≥ 1 serious adverse events · people with acute subarachnoid haemorrhage
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with ≥ 1 serious adverse events · people with acute subarachnoid haemorrhage
It is very uncertain whether induced hypertension changes proportion of participants with ≥ 1 serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Proportion of participants with ≥ 1 serious adverse events · chronic hepatitis B
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with ≥ 1 serious adverse events · chronic hepatitis B
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with 1 or more serious adverse events · chronic hepatitis B
1 finding from 1 review
Proportion of participants with 1 or more serious adverse events · chronic hepatitis B
The review found no eligible studies for this question.
1 finding from 1 review